Brand Name | Status | Last Update |
---|---|---|
allevia | unapproved drug other | 2025-02-27 |
choline c 11 | New Drug Application | 2024-12-17 |
zyrexal | unapproved drug other | 2020-02-10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | 1 | 1 | — | — | — | 1 |
Hearing loss | D034381 | EFO_0004238 | H91.9 | 1 | 1 | — | — | — | 1 |
Sensorineural hearing loss | D006319 | — | H90.5 | 1 | 1 | — | — | — | 1 |
Bilateral hearing loss | D006312 | — | — | 1 | 1 | — | — | — | 1 |
Deafness | D003638 | EFO_0001063 | H91.9 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 6 | — | — | — | — | 6 |
Non-small-cell lung carcinoma | D002289 | — | — | 4 | — | — | — | — | 4 |
Urinary bladder neoplasms | D001749 | — | C67 | 3 | — | — | — | — | 3 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | — | — | — | — | 3 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | — | — | — | — | 3 |
Triple negative breast neoplasms | D064726 | — | — | 3 | — | — | — | — | 3 |
Uterine cervical neoplasms | D002583 | — | — | 3 | — | — | — | — | 3 |
Prostatic neoplasms | D011471 | — | C61 | 2 | — | — | — | — | 2 |
Esophageal neoplasms | D004938 | — | C15 | 2 | — | — | — | — | 2 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | — | — | — | — | 2 |
Drug common name | Edrecolomab |
INN | edrecolomab |
Description | Edrecolomab (mouse mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2108955 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB13375 |
UNII ID | 0KYI9U9FSJ (ChemIDplus, GSRS) |